Controlled Human Infection Models: Is it Really Feasible to Give People Tuberculosis?

  title={Controlled Human Infection Models: Is it Really Feasible to Give People Tuberculosis?},
  author={Helen McShane},
  journal={American Journal of Respiratory and Critical Care Medicine},
  pages={1180 - 1181}
  • H. McShane
  • Published 6 January 2020
  • Biology, Medicine
  • American Journal of Respiratory and Critical Care Medicine
Tuberculosis (TB) is currently responsible for more deaths per annum than any other pathogen (1). Despite modest gains in control in recent years, the rate of progress is too slow. Data from mathematical modeling suggest that an effective vaccination strategy will be required to achieve the ambitious targets described in the Sustainable Development Goals and the Stop TB Partnership’s Global Plan to End TB (2). The recent results from the M72/AS01e efficacy trial give us some cause for optimism… 
A century of BCG: Impact on tuberculosis control and beyond
Through this review, information is attempted to bring together information on various aspects of the BCG‐induced immune response, its efficacy in TB control, comparison with other candidate TB vaccines and strategies to improve its efficiency including revaccination and alternate routes of administration.
It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity
Novel vaccine candidates advancing through either the preclinical or clinical pipeline leverage different platforms to purposefully elicit complex immune responses, and the observed role each major cell type plays in vaccine-induced immunity is categorically outlined.
Local Pulmonary Immunological Biomarkers in Tuberculosis
What is known about pulmonary specific immunological biomarkers is reviewed and potential applications and further research needs are discussed, suggesting alternative approaches may be necessary in the field of TB vaccines.
New Developments and Insights in the Improvement of Mycobacterium tuberculosis Vaccines and Diagnostics Within the End TB Strategy
This review summarizes current social challenges for TB control, and yet, recent developments in TB diagnosis and vaccines in the context of the End TB strategy and SDGs to transform global health.


Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.
Among adults infected with M. tuberculosis, vaccination with M72/AS01E elicited an immune response and provided protection against progression to pulmonary tuberculosis disease for at least 3 years, with similar frequencies in the two groups.
Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials.
  • P. Mangtani, I. Abubakar, J. Sterne
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2014
Absence of prior M. tuberculosis infection or sensitization with environmental mycobacteria is associated with higher efficacy of BCG against pulmonary tuberculosis and possibly against miliary and meningeal tuberculosis.
Preclinical Development of an In Vivo BCG Challenge Model for Testing Candidate TB Vaccine Efficacy
Results indicate that protection against a BCG skin challenge is predictive of BCG vaccine efficacy against aerosol M.tb challenge, and translation to a human BCG challenge model could enable more rapid assessment and down selection of candidate TB vaccines and ultimately the identification of an immune correlate of protection.
Controlled Human Malaria Infection: Applications, Advances, and Challenges
ABSTRACT Controlled human malaria infection (CHMI) entails deliberate infection with malaria parasites either by mosquito bite or by direct injection of sporozoites or parasitized erythrocytes. When
Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines
A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live BCG.
A lung-orientated mycobacterial controlled human infection model using live BCG and PPD is feasible and safe and inform the study of TB immunopathogenesis and strategies for evaluation and development of TB vaccine candidates.
Recruitment of antigen-specific Th1-like responses to the human lung following bronchoscopic segmental challenge with purified protein derivative of Mycobacterium tuberculosis.
Findings indicate that bronchoscopic challenge with PPD results in recruitment of antigen-specific recall responses to the lung, and may be useful in clarifying the basis of local immunity against M. tuberculosis.
Global Tuberculosis Report
  • Global Plan to Stop TB
  • 2016